We are Elixia.
As pharma’s trusted partner for patient recruitment and clinical trials management and analysis, Elixia is committed to improving the speed and efficiency of clinical trials to fuel medical breakthroughs. We envision a world where we help improve lives by making new treatments for complex diseases accessible to all communities much faster.
Rather than a CRO (clinical research organization), we call ourselves a CSO: a clinical site organization. Elixia’s deep understanding of site operations and our breakthrough approach to site management aim to reshape the traditional clinical trials landscape.
BREAKTHROUGHS FOR A BROKEN SYSTEM
“Over the last 50 years, the lack of innovation and poor execution in the clinical trials industry is what’s caused the market to be characterized as inefficient and often ineffective. With a more tailored approach, we can transform the way clinical trials showcase success across the world and ultimately help to perpetuate faster regulatory approval for new molecules that have the ability to save patient lives and improve quality of life everywhere.”
Our values
Our executive team
Neal A. Patel
Chief Executive Officer
Under his leadership, Elixia’s total enterprise value has more than quadrupled, the number of employees tripled and the company has received numerous accolades for its work across several therapeutic focuses.
Jim F. Crissy
Chief Operating Officer
In his role of COO for Elixia, Jim provides strategic direction and operational oversight to a diverse and unique system of logistics that reflects the disruptive nature of Elixia’s forward approach to clinical trials.
Sam Searcy
Chief Commercial Officer
Sam is an industry veteran who brings access to a professional network of the top CROs and pharma companies. Elixia’s disruptive model is fueled by his expertise in aligning therapeutic knowledge to client needs.
Harry Alcorn
Chief Scientific Officer
Harry masterfully orchestrates the fusion of operational strategy and scientific innovation with deep-rooted industry expertise. His command of our Early Phase Clinical Trials Division underpins Elixia’s leadership in niche-focused clinical trials.
Jennifer L. Yevoli
General Counsel
As General Counsel, Jennifer advises Elixia on a wide range of corporate, regulatory, contracting, and business issues and heads compliance and corporate integrity efforts across the organization.
WE ARE PROUD TO HAVE PARTNERED WITH
